ERBB2 and breast carcinoma: Based on the SOPHIA phase three randomized open-label trial, margetuximab plus chemotherapy had acceptable safety and significant clinical benefits compared with trastuzumab plus chemotherapy in ERBB2-positive advance breast cancer after two or more prior anti-ERBB2 therapies (16).